Yuan Y, Orlow S J, Curtin J, Downey A, Muggia F
NYU Cancer Institute and Medical Oncology, NYU Langone Medical Center, New York, NY 10016, USA.
Ecancermedicalscience. 2008;2:111. doi: 10.3332/ecancer.2008.111. Epub 2008 Dec 9.
Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a 'Stealth' (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.
聚乙二醇化脂质体阿霉素（PLD，商品名多美素、楷莱）被广泛用于治疗卵巢癌。它是一种将阿霉素包裹于“隐形”（即聚乙二醇化）脂质体中的稳定制剂，半衰期约为72小时。这种显著改变的药理学特性使其心脏毒性风险大幅降低，无急性呕吐，几乎不会出现脱发或外渗坏死问题。另一方面，PLD的剂量限制性毒性为皮肤毒性。自最初的I期报告以来，PLD报告的皮肤毒性可分为四类常见情况：广为人知的手足综合征（也称为掌跖红细胞感觉异常，或PPE）、弥漫性滤泡疹、擦烂样皮疹以及色素沉着，包括黑素斑。
